Collaborations, Conference Participation Schedules, and Upcoming Earnings Release - Research Report on Pfizer, Humana, WellPoint, Stryker, and Centene

Tue Jan 14, 2014 8:00am EST

* Reuters is not responsible for the content in this press release.

Collaborations, Conference Participation Schedules, and Upcoming Earnings Release - Research Report on Pfizer, Humana, WellPoint, Stryker, and Centene

PR Newswire

NEW YORK, January 14, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Humana Inc. (NYSE: HUM), WellPoint Inc. (NYSE: WLP), Stryker Corp. (NYSE: SYK), and Centene Corp. (NYSE: CNC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report    

On January 9, 2014, PR Newswire reported that Pfizer Inc. (Pfizer) has entered into an exclusive collaborative development agreement with The Avillion Group (Avillion) to conduct a global Phase 3 clinical trial of the Company's BOSULF (bosutinib). According to the PR Newswire report, the trial will be conducted across multiple sites in the United States, Asia and Europe, and will evaluate BOSULIF, administered at a starting dose level of 400 mg daily, as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). PR Newswire's report also mentioned that under the terms of the agreement, Avillion will provide the funding for and will conduct the trial to generate the clinical data necessary to potentially support a registration dossier for marketing authorization of BOSULIF by regulatory authorities for an indication as first-line treatment of patients with chronic phase Ph+ CML. According to the report, if approved for this indication, Avillion will be eligible to receive milestone payments from Pfizer upon regulatory approval of the drug, while the latter will retain all rights to commercialize BOSULIF globally. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/d702_PFE

--

Humana Inc. Research Report

On January 3, 2014, Humana Inc. (Humana) reported that it will release its financial results for the Q4 2013 on February 5, 2014 at 6:00 a.m. ET. According to the Company, it will host a conference call, as well as a virtual slide presentation on the same day at 9:00 a.m. ET to discuss its quarterly financial results and to provide earnings guidance for full-year 2014. The Company informed that a live virtual presentation of its Q4 2013 earnings call may be accessed via Humana's Investor Relations page. The Full Research Report on Humana Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/496b_HUM

--

WellPoint Inc. Research Report

On January 8, 2014, WellPoint Inc. (WellPoint) announced that its senior management is scheduled to make a presentation at the 32nd Annual J.P. Morgan Healthcare Conference on January 14, 2014, at 9:30 a.m. PST/ 12:30 p.m. EST. The Company informed that interested parties may to listen to a webcast of the presentation via WellPoint's website. The Full Research Report on WellPoint Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/64cd_WLP

--

Stryker Corp. Research Report  

On January 2, 2014, Stryker Corp. (Stryker) announced that it will participate at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on January 15, 2014 at 8:00 a.m. PST. The Company informed that interested parties may access a live webcast of the presentation via Stryker's website. The Full Research Report on Stryker Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5b34_SYK

--

Centene Corp. Research Report

On January 8, 2014, Centene Corp. (Centene) announced that it will release its Q4 2013 and full-year 2013 financial results on February 4, 2014 at approximately 6:00 a.m. EST, which will be followed by a conference call on the same day at approximately 8:30 a.m. EST to review the results. According to the Company, Centene's Chairman and CEO Michael F. Neidorff and Executive Vice President, CFO and Treasurer William N. Scheffel will host the aforesaid call. According to the Company, investors and other interested parties may listen to the conference call via a live, audio webcast on Centene's website.

The Full Research Report on Centene Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e85d_CNC

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.    

SOURCE Analysts' Corner

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.